Avanos Medical, Inc. (NYSE:AVNS) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. trimmed its position in shares of Avanos Medical, Inc. (NYSE:AVNS) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 570,347 shares of the company’s stock after selling 16,383 shares during the period. Prudential Financial Inc. owned approximately 1.24% of Avanos Medical worth $9,080,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Tributary Capital Management LLC increased its stake in Avanos Medical by 38.1% during the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after acquiring an additional 246,379 shares during the last quarter. Empowered Funds LLC increased its position in Avanos Medical by 141.3% during the 4th quarter. Empowered Funds LLC now owns 153,834 shares of the company’s stock worth $2,449,000 after purchasing an additional 90,091 shares in the last quarter. Barclays PLC raised its holdings in Avanos Medical by 446.2% in the third quarter. Barclays PLC now owns 96,194 shares of the company’s stock valued at $2,311,000 after buying an additional 78,583 shares during the period. Rice Hall James & Associates LLC acquired a new position in Avanos Medical during the fourth quarter valued at approximately $989,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Avanos Medical by 467.5% during the 4th quarter. Intech Investment Management LLC now owns 48,782 shares of the company’s stock valued at $777,000 after acquiring an additional 40,186 shares in the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Stock Down 2.6 %

AVNS stock opened at $13.96 on Friday. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The firm has a 50 day simple moving average of $15.66 and a 200-day simple moving average of $18.34. The company has a market capitalization of $641.97 million, a P/E ratio of 41.04 and a beta of 1.17. Avanos Medical, Inc. has a twelve month low of $13.87 and a twelve month high of $25.36.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.03. The company had revenue of $179.60 million during the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. On average, equities research analysts predict that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Insider Activity at Avanos Medical

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the transaction, the senior vice president now owns 82,047 shares of the company’s stock, valued at $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.64% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.